Patrick T.
- Country
- Germany
- Department
- Dermatology
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Phase 3 Randomized Double-Blind Study of Tucidinostat and Nivolumab Versus Placebo and Nivolumab in Metastatic or Unresectable Melanoma
- Evaluation of Neoadjuvant and Adjuvant mRNA-4157 with Pembrolizumab Versus Standard of Care in Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 69 of 175 partner sites.
Specializations
Hematologic Malignancies and Transplantation
Patrick Terheyden is involved in clinical research across acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and lymphoma, with a strong focus on treatment-resistant and relapsed disease. His work also includes myelodysplastic syndromes, myelofibrosis, and graft-versus-host disease in the setting of allogeneic hematopoietic stem cell transplantation.
- Acute myeloid leukemia
- Multiple myeloma
- Chronic lymphocytic leukemia
- Allogeneic hematopoietic stem cell transplantation
His trial portfolio also extends to post-transplant complications and high-risk hematologic disease, reflecting active interest in advanced cellular and immune-based therapy settings.
Solid Tumors and Precision Oncology
His oncology research spans non-small cell lung cancer, small cell lung cancer, melanoma, breast cancer, urothelial carcinoma, prostate cancer, hepatocellular carcinoma, and ovarian cancer. The clinical landscape includes both locally advanced and metastatic disease, with particular attention to biomarker-defined tumor subsets.
- Non-small cell lung cancer
- Melanoma
- Breast cancer
- Hepatocellular carcinoma
He is also active in studies involving targeted therapies, immunotherapy, and perioperative cancer treatment, supporting innovation in tumor-directed care.
Immune-Mediated, Inflammatory, and Dermatologic Diseases
Patrick Terheyden contributes to research in crohn's disease, ulcerative colitis, systemic lupus erythematosus, lupus nephritis, atopic dermatitis, psoriasis, hidradenitis suppurativa, bullous pemphigoid, and prurigo nodularis. This area also includes vasculitis, systemic sclerosis, and other autoimmune disorders.
- Crohn's disease
- Ulcerative colitis
- Systemic lupus erythematosus
- Atopic dermatitis
His studies in this field emphasize immune modulation and symptom control across chronic inflammatory and skin diseases.
Cardiovascular, Renal, and Metabolic Disorders
His clinical research includes atrial fibrillation, acute coronary syndrome, heart failure, aortic stenosis, atherosclerotic cardiovascular disease, chronic kidney disease, IgA nephropathy, and kidney transplantation. He is also involved in studies of obesity, prediabetes, and metabolic dysfunction-associated steatohepatitis.
- Atrial fibrillation
- Chronic kidney disease
- Kidney transplantation
- Metabolic dysfunction-associated steatohepatitis
This portfolio reflects interest in cardiorenal disease, thromboembolic risk, and metabolic complications that intersect with broader internal medicine.
Neurologic, Respiratory, and Critical Care Conditions
Patrick Terheyden is also engaged in research on acute ischemic stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer’s disease, and epileptic encephalopathies. Additional work includes acute respiratory distress syndrome, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and sepsis-associated acute kidney injury in critical care settings.
- Acute ischemic stroke
- Amyotrophic lateral sclerosis
- Idiopathic pulmonary fibrosis
- Critical care
His trial activity in these domains includes neurologic disease, respiratory failure, and intensive-care complications requiring specialized therapeutic strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.